文献速递血液净化与透析

后稀释血液透析滤过中的药物剂量:药代动力学原理与临床意义

Drug Dosing in Postdilution Hemodiafiltration: Pharmacokinetic Principles and Clinical Implications.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-07-10

本综述总结后稀释血液透析滤过(HDF)患者药物剂量的现有证据,整合药代动力学原理、临床数据及个体化治疗考虑。HDF结合弥散和对流清除,对中分子清除显著增强,但小分子清除与高通量血液透析相比仅适度改变。药物清除受分子量、蛋白结合、分布容积、膜特性及治疗参数影响,透析后补充需考虑反跳现象。

要点

  • HDF对流清除增强中分子药物清除,小分子清除较高通量血透变化不大
  • 总药物清除估算需考虑透析后反跳,大分布容积或多室动力学药物反跳明显
  • HDF特异性药代数据有限,剂量推荐常基于血透研究外推和机制推理

核心结论

  • HDF结合弥散和对流清除影响药物暴露,小分子水溶性药物清除可能增加,需个体化剂量并支持治疗药物监测。

研究设计与样本

  • 综述总结HDF患者药物剂量的当前证据,整合药代动力学原理、可用临床数据及个体化治疗的实践考虑。

主要发现

  • HDF对中分子清除显著增强,但小分子清除与高通量血液透析相比变化适度。
  • 药物清除依赖分子量、蛋白结合、分布容积、膜特性及血流量、透析液流量、对流体积等治疗参数。
  • 总药物清除估算可为透析后补充提供框架,但需考虑透析后反跳,尤其大分布容积或多室动力学药物。
  • 仅依赖透析中清除率可能高估药物消除。

临床怎么用

  • 小分子水溶性药物在HDF中预期清除更高,应基于药代动力学原理个体化剂量并辅以治疗药物监测。
  • 因HDF特异性药代数据有限,剂量推荐常需从血液透析研究外推并结合机制考虑。
  • 结构化方法整合药物特性、治疗参数和临床背景,可支持HDF患者更安全有效的用药管理。

局限性

  • HDF特异性药代动力学数据有限,剂量推荐常依赖血液透析研究外推和机制推理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Postdilution hemodiafiltration (HDF) combines diffusive and convective transport to enhance solute removal across a broad molecular weight spectrum compared with conventional high-flux hemodialysis. This review summarizes current evidence on drug dosing in patients undergoing HDF, integrating pharmacokinetic principles, available clinical data, and practical considerations for individualized therapy. Drug removal during HDF depends on multiple factors, including molecular weight, protein binding, volume of distribution, membrane characteristics, and treatment-related parameters, such as blood flow, dialysate flow, and convection volume. While the effect of HDF on small solute clearance is generally modest compared with high-flux hemodialysis, convective transport substantially enhances the removal of middle molecules. Estimation of total drug removal provides a framework for postdialysis supplementation, but interpretation must account for postdialysis rebound, particularly for drugs with large volumes of distribution or multicompartment kinetics, where redistribution may attenuate net removal. In this context, reliance on intradialytic clearance alone may overestimate drug elimination. The combined diffusive and convective clearance achieved with HDF can alter drug exposure. Higher elimination should be anticipated for small, water-soluble medications, with dosing individualized using established pharmacokinetic principles and supported by therapeutic drug monitoring. Given the limited availability of HDF-specific pharmacokinetic data, dosing recommendations often rely on extrapolation from hemodialysis studies combined with mechanistic considerations. A structured approach that integrates drug properties, treatment parameters, and clinical context may support safer and more effective medication management in patients receiving HDF.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Stuard S, Chatoth D, Mysayphonh C, et al. Drug Dosing in Postdilution Hemodiafiltration: Pharmacokinetic Principles and Clinical Implications. Clin J Am Soc Nephrol. 2026. PMID: 42455632. doi:10.2215/CJN.0000001180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。